BNB Plus Corp (OTC: BNBX) is a company in active strategic transition that holds a legacy Therapeutic DNA Production segment and a newly adopted BNB-focused digital asset treasury strategy. Revenue has historically come from DNA product sales, authentication services, and research and development services, recognized at point of delivery or over contract performance periods per Topic 606. In October 2025, the company closed a private placement receiving $26.8 million in gross proceeds plus approximately $732 thousand from warrant exercises, and launched a digital asset treasury strategy focused on BNB. Separately, it retains a Therapeutic DNA Production segment with ongoing research and development activity. The company reduced its workforce by approximately 60%, or sixteen employees, as of September 30, 2025, incurring an estimated $1.4 million in pre-tax restructuring charges and targeting annualized cost savings of approximately $2.8 million. A Strategic Digital Asset Services Agreement with a third-party Services Provider governs the BNB strategy, with Joshua Kruger serving as Chairman and Patrick Horsman appointed Chief Investment Officer on October 1, 2025.

Revenue model

Historically transactional: DNA product revenues recognized at point of transfer of control, plus service revenues from authentication and research and development contracts allocated across performance obligations by standalone selling price. The BNB digital asset treasury strategy, launched October 2025, is managed under a fee-bearing Strategic Digital Asset Services Agreement with an external Services Provider paid monthly fees, with the company holding digital assets rather than generating operating revenue from them as disclosed in the 10-K filed 2025-12-22.

Products and services

DNA products, authentication services, research and development services (Therapeutic DNA Production segment); BNB-focused digital asset treasury holdings managed under a Strategic Digital Asset Services Agreement with an external Services Provider; at-the-market common stock offering facility of up to $8,157,932 established November 4, 2025 via Lucid Capital Markets as sales agent, with 10,759 shares issued for net proceeds of $31,791 as of December 15, 2025.

Customers and end markets

Customers for the Therapeutic DNA Production segment purchase DNA products and authentication or research and development services under short-term contracts. No specific customer concentration percentages or named customers are disclosed in the excerpts from the 10-K filed 2025-12-22.

Value-chain role

Producer and service provider of DNA-based products and authentication services in the Therapeutic DNA Production segment. In the digital asset strategy, the company acts as a treasury holder of BNB, with operational management outsourced to an external Services Provider under a five-year Strategic Digital Asset Services Agreement.

Geographic exposure

Not disclosed in the filing excerpts from the 10-K filed 2025-12-22.

Source: SEC 10-K, filed 2025-12-22

Industry: Services-Testing Laboratories Peers: PRESSURE BIOSCIENCES INC Niagen Bioscience Inc Telesis Bio Inc. Reflect Scientific Inc RADNOSTIX, INC. IsoPlexis Corp Miromatrix Medical Inc. Atlantic International Corp Thermo Fisher Scientific Inc